In-stent Restenosis

Michael S Lee; Gaurav Banka

doi:10.1016/j.iccl.2015.12.006

In-stent Restenosis

Interv Cardiol Clin. 2016 Apr;5(2):211-220. doi: 10.1016/j.iccl.2015.12.006. Epub 2016 Feb 13.

Authors

Michael S Lee¹, Gaurav Banka²

Affiliations

¹ Cardiology Division, Department of Medicine, UCLA Medical Center, 100 Medical Plaza Suite 630, Los Angeles, CA 90095, USA. Electronic address: mslee@mednet.ucla.edu.
² UCLA Medical Center, Los Angeles, CA, USA.

PMID: 28582205
DOI: 10.1016/j.iccl.2015.12.006

Abstract

In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS. Predictors of ISR include patient, lesion, and procedural characteristics. Intravascular ultrasound, optical coherence tomography, and fractional flow reserve are important tools for the anatomic and hemodynamic assessment of ISR. Treatment options for ISR include percutaneous coronary intervention with DES.

Keywords: In-stent restenosis; Neointimal hyperplasia; Percutaneous coronary intervention; Target lesion revascularization; Target vessel revascularization.

Publication types

Review

MeSH terms

Cardiovascular Agents / administration & dosage*
Coronary Angiography
Coronary Restenosis / therapy*
Disease-Free Survival
Drug-Eluting Stents*
Humans
Percutaneous Coronary Intervention / adverse effects
Percutaneous Coronary Intervention / instrumentation*
Prosthesis Design
Risk Factors
Treatment Outcome

Substances

Cardiovascular Agents